Stock Idea…Medicure Inc

Stock Idea…Medicure Inc

Symbol : MPH

Exchange: TSXV

Market Cap : 112 Million

Revenue : 38 Million
Three Year Revenue Growth : 110.7 %
Investment Type : Micro Cap Value/Growth

Price/Earnings : 4.7

Forward P/E : 8.6

Price/Book : 5.4

Price/Sales : 3.5

Price/Cash Flow : 4.4

Price : 7.16
Investment Stem : Cheap Small Caps Screen
                                Pender Small Cap Opportunities Fund

Medicure Inc is in the business of research, clinical development and commercialization of human therapeutics for United States hospital market. It has Marketing and distribution of Aggrastat and Manufacturing and distribution of API segments.

Medicure Inc. (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company's primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company's United States subsidiary, Medicure Pharma, Inc. AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS). The Company is also engaged in the development of TARDOXAL for neurological disorders, such as Tardive Dyskinesia (TD). The Company has completed Phase IIa stage of development for TARDOXAL. The Company is also developing Transdermal AGGRASTAT, a cure for acute cardiology. Transdermal AGGRASTAT is in preclinical-stage of development.

The dreaded metrics from Morningstar…

http://quote.morningstar.ca/Quicktakes/stock/keyratios.aspx?t=MPH&region=CAN&culture=en-CA&ops=clear

The company’s website…

http://www.medicure.com/

Medicure is a pharmaceutical company focused on the development and commercialization of cardiovascular therapeutics for the U.S. market

Medicure’s vision is to become a leading cardiovascular pharmaceutical company within the U.S, offering a growing product portfolio of cardiovascular products that improve patients’ lives. We have an unwavering focus on delivering safe, efficacious and cost-effective medicines that benefit patients, healthcare providers and shareholders. Our commitment to service, partnership and integrity is what sets us apart.

Medicure was established in 1997, and spent its first decade focused on research and development. In 2008, the company began a transition to focus on its commercial pharmaceutical business. This new direction has provided significant shareholder value with the growth of AGGRASTAT sales, achieving profitability, and the pursuit of development and acquisition opportunities.

Medicure’s board and management is committed to building value for its existing shareholder base and is patiently pursuing a long-term view to establishing the Company as a leading, international pharmaceutical company - one that is distinguished by its unique fit within the contemporary market.

Medicure Inc. is based in Winnipeg, Canada and publicly traded on the Toronto Stock Exchange Venture under the symbol MPH. Its subsidiaries include Medicure International, Inc. (Barbados), which owns the U.S. rights to AGGRASTAT, as well as two U.S. corporations, Medicure USA, Inc. and Medicure Pharma, Inc., which distributes the Company’s products in the United States.